Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047837 | 1.00 | KEAP1 (0.50) | KEAP1NFE2L2GRIK1CXCL8CYP2C9 | |
| SCHEMBL25253767 | 0.93 | KEAP1 (0.45) | KEAP1NFE2L2GRIK1CXCL8CYP2C9 | |
| SCHEMBL9596857 | 0.85 | PYCR1 (0.41) | KEAP1NFE2L2GRIK1PPARAPYCR1 | |
| SCHEMBL30452345 | 0.85 | PYCR1 (0.41) | KEAP1NFE2L2GRIK1PPARAPYCR1 | |
| SCHEMBL1614038 | 0.85 | KEAP1 (0.50) | KEAP1NFE2L2GRIK1CXCL8CYP2C9 | |
| SCHEMBL29761218 | 0.85 | KEAP1 (0.50) | KEAP1NFE2L2GRIK1CXCL8CYP2C9 | |
| SCHEMBL22122719 | 0.83 | PYCR1 (0.44) | GRIK1CYP2C9PPARAPYCR1MAPT | |
| SCHEMBL4706380 | 0.83 | SIRT1 (0.45) | PPARAPYCR1MAPTTDP1L3MBTL1 | |
| SCHEMBL30485967 | 0.83 | PYCR1 (0.44) | GRIK1CYP2C9PPARAPYCR1MAPT | |
| SCHEMBL16041940 | 0.82 | KEAP1 (0.54) | KEAP1NFE2L2GRIK1CXCL8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| CN-118488947-A | Condensed ring substituted six-membered heterocyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-113227089-B | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116745288-A | Compounds and uses thereof | 福霍恩治疗公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-113912597-B | ROR gamma inhibitor, preparation method and medical application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | KEAP1 1240/4885NFE2L2 744/4885GRIK1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.